Table 4 Secondary efficacy measures
Combined suppression of nightmares and intrusions | |
|---|---|
Responder status, n (%) | |
Full | 26/33 (79%) |
Partial | 3/33 (9%) |
None | 4/33 (12%) |
Mean time to response, days ± SD, (range) | |
Full response (n = 25) | 15 ± 18 (1–83) |
Partial response (n = 17) | 11 ± 13 (2–46) |
Median time to full response, days | 9 |
Median time to partial response, days | 5 |
Mean dosage at time of response, mg/day | |
Full response | 60 ± 47 |
Partial response | 32 ± 15 |
Median dosage at time of response, mg/day | |
Full response | 50 |
Partial response | 25 |
Modal daily dosage for full response, mg/day | 25 |
% of patients in the 12.5–50-mg/day range | 65 |
Modal dosage at time of partial response, mg/day | 25 |
% of patients in the 12.5–50-mg/day range | 100 |
Improvements in nightmares | |
Full cessation of nightmares | 17/18 (94%) |
Improvements in intrusions | |
Full cessation of intrusions | 26/33 (79%) |
Partial improvement | 3/33 (9%) |
No improvement | 4/33 (12%) |